# Press release

Please fill in this form and return it to [graduateschoolhealth@au.dk](mailto:graduateschoolhealth@au.dk) in Word format no later than three weeks prior to your defence.

## Basic information

Name: Andreas Lodberg        Email: andreas@biomed.au.dk Phone: 53659060

Department of: Biomedicine

Main supervisor: Annemarie Brüel

Title of dissertation: Targeting members of the TGFβ superfamily to achieve bone and skeletal muscle anabolism

Date for defence: 27/8/21 at (time of day): 14.00 Place: Det Blå Auditorium, Viktor Albeck Bygningen (lok 222, bygn 1266)

Press release (Danish)
Neutralisering af TGFβ-superfamiliemedlemmer som behandling af muskel- og knogletab.

Tab af knogle- og muskelmasse forekommer ofte samtidigt. Begge tilstande kan lede til svær morbiditet og nedsat funktionsevne. Dødeligheden efter hoftebrud er op til 30% i det første år, og der er derfor brug for nye behandlinger til at forbedre forløbet. Neutralisering af tre medlemmer af TGFβ superfamilien, activin A, growth differentiation factor 11 og myostatin, fremstår som en lovende tilgang til at forhindre tab af knogle- og muskelmasse. Et nyt ph.d.-projekt fra Aarhus Universitet, Health har undersøgt terapeutisk hæmning af vækstfaktorene i dyremodeller for knogletab. Projektet er gennemført af Andreas Lodberg, der forsvarer det d. 27/8/21

Forsvaret af ph.d.-projektet er offentligt og finder sted den 27/8/21 kl. 14.00 i "Det Blå Auditorium", Viktor Albeck Bygningen, Aarhus Universitet, Vejnavn, By. Titlen på projektet er "Targeting members of the TGFβ superfamily to achieve bone and skeletal muscle anabolism". Yderligere oplysninger: Ph.d.-studerende Andreas Lodberg, e-mail: andreas@biomed.au.dk, tlf. 53659060.

Bedømmelsesudvalg:
Chairman of the committee
Professor, Lars Rejnmark, MD, PhD, DMSc
Department of Endocrinology
Aarhus University and Aarhus University Hospital, Denmark

Assessor
Professor, Moustapha Kassem, MD, PhD, DMSc
Department of Endocrinology
University of Southern Denmark and University Hospital of Odense, Denmark

Assessor
Professor, Jens Bollerslev, MD, DMSc
Department of Endocrinology
University of Oslo and Oslo University Hospital, Norway

Press release (English)
Targeting members of the TGFβ superfamily to achieve bone and skeletal muscle anabolism

Bone loss and muscle wasting are two conditions that often coincide. Both conditions may lead to severe disability and morbidity. For hip fractures, the first-year mortality rate is a staggering 30% and new therapies are therefore urgently needed to improve patient outcomes. Three members of the

TGFβ superfamily: activin A, growth differentiation factor 11, and myostatin have emerged as promising therapeutic targets in musculoskeletal disease. A new PhD project from Aarhus University, Health has investigated inhibition of these growth factors to combat musculoskeletal wasting in mouse models. The project was carried out by Andreas Lodberg who is defending his dissertation on 27/8-21.

The defence is public and takes place on 27/8 at 14:00 in "Det Blå Auditorium", Aarhus University, Road, City. The title of the project is "Targeting members of the TGFβ superfamily to achieve bone and skeletal muscle anabolism". For more information, please contact PhD student Andreas Lodberg, email: andreas@biomed.au.dk, Phone +45 53659060.

Assessment committee:
Chairman of the committee
Professor, Lars Rejnmark, MD, PhD, DMSc
Department of Endocrinology
Aarhus University and Aarhus University Hospital, Denmark

Assessor
Professor, Moustapha Kassem, MD, PhD, DMSc
Department of Endocrinology
University of Southern Denmark and University Hospital of Odense, Denmark

Assessor
Professor, Jens Bollerslev, MD, DMSc
Department of Endocrinology
University of Oslo and Oslo University Hospital, Norway


**Permission**

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.